NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures 08/19/10 NOVAVAX to Present at the Immunotherapeutics and Vaccine (IMVAC) Summit 08/17/10 Novavax Reports Positive Results from Pre-clinical Safety Study of Respiratory Syncytial Virus (RSV) Vaccine Candidate 08/12/10 NOVAVAX Elects Richard H. Douglas to its Board of Directors 08/06/10 Novavax Reports Second Quarter 2010 Financial Results 08/06/10 Novavax to Report Second Quarter 2010 Financial Results 07/30/10 NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines 07/27/10 Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 07/06/10